Medical note: This article is educational and does not replace advice from a neurologist, pharmacist, or other qualified health professional. Teriflunomide is a prescription medication with boxed warnings, required laboratory monitoring, and potentially serious drug interactions. Never start, stop, or change the dose without medical guidance.
Teriflunomide, best known by the brand name Aubagio, is an oral disease-modifying therapy for adults with relapsing forms of multiple sclerosis. The convenience is obvious: one tablet a day, no needles, and no need to schedule your life around an infusion chair. However, “convenient” does not mean “casual.” Teriflunomide can affect the liver, blood cells, blood pressure, nerves, lungs, skin, pregnancy, and the way several other medicines behave in the body.
The current U.S. prescribing information includes boxed warnings for serious liver injury and harm to an unborn baby. In February 2026, the label was also updated to warn about skin or mucosal ulcers and impaired wound healing. In other words, this is not a pill that should quietly disappear into the back of a medicine cabinet while everyone forgets it exists. Regular monitoring matters.
What Is Teriflunomide?
Teriflunomide is an immunomodulatory medication with anti-inflammatory properties. It inhibits an enzyme called dihydroorotate dehydrogenase, which is involved in producing pyrimidines needed by rapidly dividing cells. The exact way this improves multiple sclerosis is not fully understood, but the effect may reduce the number of activated immune cells capable of contributing to inflammation in the central nervous system.
It does not broadly switch off the immune system like a master light switch. A better analogy is that it slows down part of the immune system’s overenthusiastic production line. That can help reduce MS disease activity, although it can also lower certain blood-cell counts and increase susceptibility to some infections.
What Is Teriflunomide Used For?
In the United States, teriflunomide is approved for adults with relapsing forms of multiple sclerosis, including:
- Clinically isolated syndrome, or CIS
- Relapsing-remitting multiple sclerosis
- Active secondary progressive multiple sclerosis
Teriflunomide is intended to reduce relapses and disease activity. It is not a cure for MS, and it does not instantly reverse symptoms that are already present. Clinical trials found reductions in annualized relapse rates and MRI disease activity compared with placebo. The 14 mg dose also demonstrated benefits on sustained disability progression in key studies.
Teriflunomide Dosing and Administration
Usual adult dose
The recommended U.S. dose is either 7 mg or 14 mg taken by mouth once daily. It may be taken with or without food, and no starter-dose titration is required. Taking it at approximately the same time each day can make adherence easier. A phone reminder is often more reliable than the classic strategy of “surely I will remember,” which has disappointed humanity for generations.
The prescriber selects the strength based on the expected benefit, tolerability, medical history, laboratory results, and the patient’s overall MS treatment plan. Patients should not switch between 7 mg and 14 mg without speaking to the prescribing clinician.
What to do after a missed dose
Take a missed dose when you remember it unless it is nearly time for the next scheduled dose. In that case, skip the missed tablet and resume the normal schedule. Do not take two doses together or add an “extra” tablet to compensate.
Dosing with kidney or liver impairment
No dose adjustment is generally required for mild, moderate, or severe renal impairment. No adjustment is listed for mild or moderate hepatic impairment, but teriflunomide is contraindicated in severe hepatic impairment. Patients with existing liver disease or elevated liver enzymes may require a different treatment because their risk of liver injury can be higher.
What Do Aubagio Tablets Look Like?
Brand-name Aubagio tablets have distinct shapes and markings:
- Aubagio 14 mg: A pale blue to pastel-blue, pentagonal, film-coated tablet with “14” on one side and the corporate logo on the other.
- Aubagio 7 mg: A very light greenish-blue-gray to pale greenish-blue, hexagonal, film-coated tablet with “7” on one side and the corporate logo on the other.
Generic teriflunomide tablets may look different depending on the manufacturer. Some are white or off-white, while others may be blue, round, pentagonal, or hexagonal, with manufacturer-specific letters and numbers. Packaging can also vary between bottles and blister cards.
Never identify an unknown tablet by color alone. Lighting, coatings, generic manufacturers, and camera filters can all turn “pale blue” into anything from gray to swimming-pool turquoise. Verify the imprint, strength, packaging, and pharmacy label, or ask a pharmacist before taking it.
Common Teriflunomide Side Effects
The most commonly reported reactions in pooled placebo-controlled trials included headache, increased alanine aminotransferase or ALT, diarrhea, hair thinning or hair loss, nausea, tingling sensations, joint pain, neutropenia, and hypertension.
Trial rates varied by dose. For example, diarrhea occurred in 13% of patients taking 7 mg and 14% taking 14 mg, compared with 8% receiving placebo. Alopecia was reported in 10% and 13%, respectively, versus 5% with placebo. Nausea occurred in 8% and 11%, compared with 7% for placebo. These percentages describe groups in clinical trials; they cannot predict exactly what one individual will experience.
Hair thinning
Hair thinning is one of the better-known concerns. It is often described as diffuse thinning rather than sharply defined bald patches. Patients should mention it at follow-up visits, especially if it becomes severe, persistent, or accompanied by other symptoms. Other causes such as thyroid disease, nutritional deficiencies, stress, and unrelated medications may also need consideration.
Digestive symptoms
Diarrhea, nausea, and stomach discomfort may be more noticeable early in treatment. Taking the tablet with food can be helpful for some patients, although food is not required. Persistent diarrhea, dehydration, severe abdominal pain, vomiting, bloody stools, or symptoms suggesting pancreatitis or colitis warrant medical attention.
Serious Warnings and Side Effects
Serious liver injury
Teriflunomide carries a boxed warning for hepatotoxicity. Potentially life-threatening liver injury, including acute liver failure requiring transplantation, has been reported after approval. Risk may be higher in people with preexisting liver disease or those taking other medicines that can damage the liver.
Seek prompt medical advice for unexplained nausea, vomiting, loss of appetite, unusual fatigue, upper abdominal pain, yellow skin or eyes, or dark urine. Liver injury can occur at any point during therapy, so normal results during the first few months are reassuring but not a lifelong force field.
Pregnancy and fetal harm
Teriflunomide is contraindicated during pregnancy and in females of reproductive potential who are not using effective contraception. Pregnancy must be excluded before treatment begins. Effective contraception should continue during therapy and after discontinuation until blood testing confirms that the teriflunomide concentration is below 0.02 mg/L.
Men who wish to father a child should also speak with their clinician. Teriflunomide is detectable in semen, and the label advises either completing an accelerated elimination procedure or waiting until the blood concentration has been verified below the target level. Breastfeeding is not recommended during treatment.
Low blood-cell counts and infections
Teriflunomide can reduce white blood cells and platelets. Patients with an active acute or chronic infection should generally wait until it has resolved before beginning treatment. Fever, persistent cough, painful urination, unusual bruising, or other signs of infection or blood-cell abnormalities should be reported.
Screening for latent tuberculosis is required before treatment. Live vaccines are not recommended during therapy, and the drug’s long persistence in the body must be considered when planning a live vaccine after discontinuation.
Severe allergic and skin reactions
Rare but serious reactions include anaphylaxis, angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS, a drug reaction that can affect multiple organs. Emergency symptoms include trouble breathing, swelling of the lips or tongue, a rapidly spreading rash, skin blistering or peeling, facial swelling, fever, or swollen lymph nodes.
The February 2026 U.S. label added a warning about skin or mucocutaneous ulcers and impaired wound healing. Persistent skin sores, mouth ulcers, wounds that do not heal normally, or upcoming surgery should be discussed with the prescribing team. Treatment may need to be paused or eliminated more rapidly under medical supervision.
Nerve, blood-pressure, and lung problems
Teriflunomide has been associated with peripheral neuropathy, including persistent numbness, burning, or tingling in the hands or feet. Risk may be greater in older adults, people with diabetes, and those using other neurotoxic medicines. It can also raise blood pressure, so periodic blood-pressure checks are recommended.
New or worsening cough, shortness of breath, or breathing symptoms with or without fever require assessment because interstitial lung disease has been reported after marketing.
Tests Needed Before and During Treatment
Before prescribing teriflunomide, clinicians typically review the patient’s medications, medical history, infection risks, reproductive plans, and vaccination status. The U.S. label calls for:
- Liver transaminase and bilirubin testing within six months before starting
- A complete blood count within six months before starting
- Screening for latent tuberculosis
- A pregnancy test for females of reproductive potential
- A baseline blood-pressure measurement
ALT should be checked at least monthly for the first six months. Additional liver monitoring may be appropriate when other potentially hepatotoxic medications are used. Blood pressure should be assessed periodically, while later blood counts may be ordered according to symptoms, infection concerns, or the clinician’s monitoring protocol.
Important Teriflunomide Drug Interactions
Teriflunomide can alter drug-metabolizing enzymes and transport proteins, so the interaction list extends beyond obvious MS medications. Always provide the prescriber and pharmacist with a complete list of prescriptions, over-the-counter medicines, vitamins, and supplements.
Medicines that need particular attention
- Leflunomide: Must not be used with teriflunomide.
- Warfarin: Teriflunomide may reduce peak INR, requiring close INR monitoring.
- Rosuvastatin: The dose should not exceed 10 mg once daily while taking Aubagio.
- Other statins: Atorvastatin, pravastatin, and simvastatin may require closer monitoring or dose changes.
- Diabetes medicines: Exposure to repaglinide, pioglitazone, and rosiglitazone may increase.
- Duloxetine, theophylline, and tizanidine: Their exposure may decrease.
- Methotrexate, ciprofloxacin, furosemide, and certain antibiotics: Drug levels may rise through transporter interactions.
- Immunosuppressive medicines: Combined effects may increase infection or blood-cell risks.
- Live vaccines: Generally avoided during treatment.
Teriflunomide may increase exposure to ethinyl estradiol and levonorgestrel. This does not mean patients should improvise a new contraceptive plan at home; the prescriber should assess the most appropriate type and dose. Medicines with liver toxicity, including certain prescription drugs and high or repeated doses of acetaminophen, deserve special review.
Why Teriflunomide Can Remain in the Body for So Long
After treatment stops, teriflunomide is eliminated slowly. Without a washout procedure, reaching a very low blood concentration takes an average of about eight months and may take as long as two years in some people.
When rapid removal is medically necessary, the prescribing information describes an 11-day procedure using either cholestyramine or activated charcoal. These regimens can reduce blood concentrations by more than 98%. They must be directed by a healthcare professional because the doses are specific, side effects can occur, laboratory confirmation may be necessary, and rapid elimination could permit MS disease activity to return.
Practical Treatment Experience: What the First Months May Feel Like
The following section describes common practical themes based on prescribing guidance and patient-care routines. It is a composite overview, not a testimonial or a prediction of any individual’s experience.
Before the first tablet
Starting teriflunomide often feels less like simply collecting a prescription and more like preparing a small launch checklist. There may be blood work, a tuberculosis screen, a blood-pressure reading, a pregnancy test when applicable, a vaccine review, and a careful discussion of every medicine already being taken. This can seem like a lot of preparation for one small tablet, but the tablet has a long memory: teriflunomide can remain in the body for months or years.
Many patients find it helpful to choose a consistent dosing cue, such as breakfast, brushing their teeth, or an evening medication organizer. Once-daily dosing is convenient, but convenience only works when the tablet actually makes it from the bottle into the patient.
The first several weeks
Early treatment may be uneventful. Other patients notice loose stools, mild nausea, headache, or temporary hair thinning. Because MS itself can cause fatigue, tingling, and other neurologic symptoms, it may be difficult to decide whether a new sensation comes from the disease, the medication, yesterday’s terrible sleep, or all three joining forces.
A simple symptom diary can help. Recording the dose time, digestive symptoms, unusual tingling, blood-pressure readings, infections, and newly started medicines gives the clinical team something more useful than “I felt strange sometime last Tuesday.” Symptoms that are severe, rapidly worsening, or associated with rash, breathing difficulty, jaundice, fever, or facial swelling should not wait for the next routine appointment.
The six-month laboratory rhythm
Monthly liver testing during the first six months becomes a central part of the routine. For some people, the hardest part is not the medication but remembering laboratory appointments. Scheduling all six visits early, setting calendar alerts, and using the same laboratory can reduce missed testing.
Normal results can provide reassurance, but they do not eliminate the need to report symptoms between tests. Conversely, an abnormal ALT result does not automatically mean catastrophic liver failure. Clinicians usually consider the degree of elevation, repeat testing, symptoms, alcohol use, infections, supplements, and other medications before deciding what happens next.
Living normally while staying alert
Travel is usually manageable with planning. Keep tablets in labeled pharmacy packaging, carry enough for delays, and maintain the normal schedule across time zones as closely as practical. Before receiving vaccines, starting antibiotics, changing cholesterol treatment, using herbal products, or preparing for surgery, remind the healthcare professional that teriflunomide is being taken.
The newer warning about impaired wound healing makes communication before planned procedures especially important. A small dental procedure, a major operation, and an unhealed skin ulcer are not identical situations, so the decision must be individualized rather than solved by an internet checklist.
Evaluating whether it is working
Teriflunomide does not usually produce a dramatic daily sensation that announces, “Congratulations, your MS therapy is active.” Success is judged over time through relapses, neurologic examinations, MRI findings, disability measures, tolerability, and quality of life. Feeling the same may be a perfectly meaningful outcome when the goal is to prevent future inflammatory activity.
The best experience tends to come from treating the medication as a partnership rather than a solo mission: take it consistently, complete monitoring, report meaningful changes, and discuss pregnancy plans, interactions, infections, surgery, or troublesome side effects early. That may not sound glamorous, but in long-term MS care, reliable routines regularly outperform glamorous intentions.
Conclusion
Teriflunomide offers adults with relapsing multiple sclerosis a convenient once-daily oral treatment that can reduce relapses and MRI disease activity. Its simplicity comes with important responsibilities: liver tests, infection screening, blood-pressure monitoring, pregnancy prevention, medication-interaction reviews, and prompt reporting of serious skin, nerve, breathing, or wound-healing problems.
The most important rule is not to manage teriflunomide in isolation. A neurologist and pharmacist should guide dose selection, laboratory monitoring, contraception planning, interaction management, and any decision to stop treatment or begin accelerated elimination.